Roche Pays $700 Million Upfront in $2.3 Billion Nurix Drug Deal
Nurix Therapeutics secures $700 million upfront and up to $1.6 million in milestones for its BTK-degrading drug partnership. Roche agreed to a $2.3 billion deal with Nurix Therapeutics for its BTK-degrading drug, bex-deg, including $700 million upfront. The agreement also